Brainomix
Developer of AI-based medical imaging software and quantitative imaging biomarkers for stroke and fibrosing lung disease. Provides automated analysis for CT and MRI modalities, enterprise analytics, mobile/web clinical review, and life-science imaging services for clinical development. Supports on-premises and cloud deployment, maintains regulatory clearances for clinical use, and reports peer-reviewed clinical evidence and large-scale real-world deployments.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
AI imaging suite for acute stroke workflows
Comprehensive AI imaging software that automates analysis across NCCT, CTA, CTP and MRI for acute stroke triage and treatment support; integrates with PACS and mobile/web apps to deliver annotated results and notifications.
AI lung CT quantification platform
Regulatory-cleared software to identify and quantify lung CT features and produce quantitative biomarkers for detection and monitoring of progressive pulmonary fibrosis.
Enterprise network analytics platform
Platform that converts AI outputs into operational and clinical intelligence for network benchmarking, clinician engagement metrics and site performance monitoring.
360 e-MRI
An FDA-cleared and European MDR-certified visualization and processing tool providing analysis and viewing capabilities for Diffusion Weighted Imaging (DWI), DWI-FLAIR mismatch, and Dynamic Susceptibility Contrast (DSC) perfusion for acute ischemic stroke patients.
Brainomix 360 e-Lung
FDA-cleared AI that automatically identifies and quantifies features on CT lung scans, helping clinicians detect subtle changes across multiple timepoints.
Brainomix 360 NCCT
An AI-powered stroke imaging software platform that provides automated ASPECTS scoring, quantification of ischemic core, and detection of intracranial hemorrhage and large vessel occlusions on non-contrast CT scans.
AI imaging suite for acute stroke workflows
Comprehensive AI imaging software that automates analysis across NCCT, CTA, CTP and MRI for acute stroke triage and treatment support; integrates with PACS and mobile/web apps to deliver annotated results and notifications.
AI lung CT quantification platform
Regulatory-cleared software to identify and quantify lung CT features and produce quantitative biomarkers for detection and monitoring of progressive pulmonary fibrosis.
Enterprise network analytics platform
Platform that converts AI outputs into operational and clinical intelligence for network benchmarking, clinician engagement metrics and site performance monitoring.
360 e-MRI
An FDA-cleared and European MDR-certified visualization and processing tool providing analysis and viewing capabilities for Diffusion Weighted Imaging (DWI), DWI-FLAIR mismatch, and Dynamic Susceptibility Contrast (DSC) perfusion for acute ischemic stroke patients.
Brainomix 360 e-Lung
FDA-cleared AI that automatically identifies and quantifies features on CT lung scans, helping clinicians detect subtle changes across multiple timepoints.
Brainomix 360 NCCT
An AI-powered stroke imaging software platform that provides automated ASPECTS scoring, quantification of ischemic core, and detection of intracranial hemorrhage and large vessel occlusions on non-contrast CT scans.
Services
Deployment of automated analysis across NCCT, CTA, CTP and MRI to support triage and treatment selection, integrate with PACS and deliver annotated results via web, mobile or email.
Automated detection, segmentation and quantification of lung CT biomarkers to support earlier detection and longitudinal monitoring in clinical practice and as imaging endpoints in trials.
Hosted dashboard that aggregates imaging AI outputs across sites to provide real-time visibility on outcomes, clinician adoption, throughput and quality assurance statistics for network management.
Specialty imaging support for multi-centre clinical trials including core lab analytics, AI-enhanced cohort evaluation for eligibility and safety assessments, bespoke biomarker and software development, medical and imaging consulting for trial design and data interpretation, patient selection/enrichment software, and integration with CRO workflows.
Deployment of automated analysis across NCCT, CTA, CTP and MRI to support triage and treatment selection, integrate with PACS and deliver annotated results via web, mobile or email.
Automated detection, segmentation and quantification of lung CT biomarkers to support earlier detection and longitudinal monitoring in clinical practice and as imaging endpoints in trials.
Hosted dashboard that aggregates imaging AI outputs across sites to provide real-time visibility on outcomes, clinician adoption, throughput and quality assurance statistics for network management.
Specialty imaging support for multi-centre clinical trials including core lab analytics, AI-enhanced cohort evaluation for eligibility and safety assessments, bespoke biomarker and software development, medical and imaging consulting for trial design and data interpretation, patient selection/enrichment software, and integration with CRO workflows.
Expertise Areas
- AI-driven clinical decision support for acute stroke
- Quantitative CT biomarkers for pulmonary fibrosis
- Clinical validation and multicentre real-world studies
- Medical image segmentation, perfusion mapping and motion correction
Key Technologies
- Deep learning for medical image analysis
- Multi-modal imaging (NCCT, CTA, CTP, MRI)
- Perfusion parameter mapping (CBF, Tmax, rCBF)
- Voxel-wise quantitative analysis
News & Updates
Large real-world observational study reporting associations between imaging AI decision support and increased mechanical thrombectomy rates and reduced transfer times.
Maintains an indexed library of peer-reviewed publications and study summaries validating imaging biomarkers and software performance (80+ publications reported).
Reported multi-site and national deployments with more than 3.5 million scans analysed across stroke and lung imaging pathways.
Multiple regulatory clearances for clinical use in several markets, including FDA clearance and CE marking.
Recipient of a Red Dot design award recognising usability and design of the next-generation stroke imaging platform.
Reported total of £49M raised in private investment and public funding.
Large real-world observational study reporting associations between imaging AI decision support and increased mechanical thrombectomy rates and reduced transfer times.
Maintains an indexed library of peer-reviewed publications and study summaries validating imaging biomarkers and software performance (80+ publications reported).
Reported multi-site and national deployments with more than 3.5 million scans analysed across stroke and lung imaging pathways.
Multiple regulatory clearances for clinical use in several markets, including FDA clearance and CE marking.
Recipient of a Red Dot design award recognising usability and design of the next-generation stroke imaging platform.
Reported total of £49M raised in private investment and public funding.